A research team at Vanderbilt University School of Medicine has partnered with Acorda Therapeutics to evaluate the safety and efficacy of a new biological product that has the potential to treat patients with even severe, progressive heart failure.

The Charles & Barbara Duboc Cardio Health & Wellness Center is ushering in a new era for preventive cardiac care at Saint Luke's Hospital..

The American Heart Association (AHA) has awarded world-renowned cardiologist Dr. Valentin Fuster, MD, PhD, Director of Mount Sinai Heart at The Mount Sinai Medical Center, its prominent American Heart Association/American Stroke Association Ron Haddock International Impact Award.

The FDA has approved Rixubis, the first recombinant coagulation factor IX, for use in people 16 years of age and older with hemophilia B.

Death rates from coronary heart disease have plunged over 30 years in Europe. But analysts in a study published June 25 in the European Heart Journal detected glimmers of a reversal in some countries within the European Union (EU).

The U.K.’s National Institute for Health and Care Excellence (NICE) has recommended the anticoagulant rivaroxaban as a possible treatment for adults with pulmonary embolism and to prevent recurrent deep vein thrombosis or pulmonary embolism.

Japan’s regulatory body has approved Edwards Lifesciences’ Sapien XT valve for surgical aortic valve replacement.

Overweight or obese adults with type 2 diabetes who lost on average 6 percent of their body weight over about 10 years were no less at risk of cardiovascular disease than people who received diabetes support and education. But the intensive lifestyle intervention did improve their glycated hemoglobin levels, according to results published June 24 in the New England Journal of Medicine.